BR112015023020A2 - combination of egfr t790m inhibitor and egfr inhibitor for the treatment of non-small cell lung cancer - Google Patents

combination of egfr t790m inhibitor and egfr inhibitor for the treatment of non-small cell lung cancer

Info

Publication number
BR112015023020A2
BR112015023020A2 BR112015023020A BR112015023020A BR112015023020A2 BR 112015023020 A2 BR112015023020 A2 BR 112015023020A2 BR 112015023020 A BR112015023020 A BR 112015023020A BR 112015023020 A BR112015023020 A BR 112015023020A BR 112015023020 A2 BR112015023020 A2 BR 112015023020A2
Authority
BR
Brazil
Prior art keywords
inhibitor
egfr
combination
lung cancer
small cell
Prior art date
Application number
BR112015023020A
Other languages
Portuguese (pt)
Inventor
Charles Kath John
Lawrence Weinrich Scott
Paul Letrent Stephen
Iris Goldberg Zelanna
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of BR112015023020A2 publication Critical patent/BR112015023020A2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

resumo “combinação de inibidor de egfr t790m e inibidor de egfr para o tratamento de câncer pulmonar de células não-pequenas” esta invenção refere-se a um método de tratamento de cancro do pulmão de células não-pequenas por administração de uma combinação de um inibidor de egfr t790m em combinação com uma quantidade de baixa dose de um inibidor de panher. esta invenção também se relaciona com um método de tratamento de cancro do pulmão de células não-pequenas através da administração de uma combinação de um inibidor de egfr t790m irreversível em combinação com um inibidor de egfr.abstract "combination of t790m egfr inhibitor and egfr inhibitor for the treatment of non-small cell lung cancer" This invention relates to a method of treating non-small cell lung cancer by administering a combination of a egfr inhibitor t790m in combination with a low dose amount of a panher inhibitor. this invention also relates to a method of treating non-small cell lung cancer by administering a combination of an irreversible t790m egfr inhibitor in combination with an egfr inhibitor.

BR112015023020A 2013-03-14 2014-03-03 combination of egfr t790m inhibitor and egfr inhibitor for the treatment of non-small cell lung cancer BR112015023020A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361786130P 2013-03-14 2013-03-14
PCT/IB2014/059401 WO2014140989A2 (en) 2013-03-14 2014-03-03 Combination of an egfr t790m inhibitor and an egfr inhibitor for the treatment of non-small cell lung cancer

Publications (1)

Publication Number Publication Date
BR112015023020A2 true BR112015023020A2 (en) 2017-07-18

Family

ID=50288209

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015023020A BR112015023020A2 (en) 2013-03-14 2014-03-03 combination of egfr t790m inhibitor and egfr inhibitor for the treatment of non-small cell lung cancer

Country Status (14)

Country Link
EP (1) EP2968336A2 (en)
JP (1) JP2014177456A (en)
KR (1) KR20150119210A (en)
CN (1) CN105073116A (en)
AR (1) AR095197A1 (en)
AU (1) AU2014229468A1 (en)
BR (1) BR112015023020A2 (en)
CA (1) CA2904797A1 (en)
IL (1) IL240730A0 (en)
MX (1) MX2015012106A (en)
RU (1) RU2015137596A (en)
SG (1) SG11201506531WA (en)
TW (1) TW201446248A (en)
WO (1) WO2014140989A2 (en)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103814030A (en) 2011-09-22 2014-05-21 辉瑞大药厂 Pyrrolopyrimidine and purine derivatives
CN104311573B (en) 2013-09-18 2017-12-15 北京韩美药品有限公司 Suppress the compound of BTK and/or JAK3 kinase activities
UA115388C2 (en) 2013-11-21 2017-10-25 Пфайзер Інк. 2,6-substituted purine derivatives and their use in the treatment of proliferative disorders
TW201622744A (en) 2014-03-04 2016-07-01 美國禮來大藥廠 Combination therapy for cancer
EP3201190A4 (en) 2014-10-01 2018-03-14 Sun Pharmaceutical Industries Ltd Crystalline form of afatinib dimaleate
CN107427515B (en) * 2014-12-03 2021-11-16 奥克兰联合服务有限公司 Kinase inhibitor prodrugs for the treatment of cancer
KR102183356B1 (en) * 2015-08-11 2020-11-27 프린시피아 바이오파마, 인코퍼레이티드 Methods for making FGFR inhibitors
US10583142B2 (en) 2016-03-25 2020-03-10 OSI Pharmaceuticals, LLC Pulse dosing regimen and methods of treatment
WO2017164887A1 (en) * 2016-03-25 2017-09-28 OSI Pharmaceuticals, LLC Pulse dosing regimen and methods for treatment
WO2017176565A1 (en) 2016-04-07 2017-10-12 Eli Lilly And Company Combinations of an anti-b7-h1 antibody and a cxcr4 peptide antagonist for treating a solid tumor
WO2017200016A1 (en) * 2016-05-17 2017-11-23 公益財団法人がん研究会 Therapeutic agent for lung cancer that has acquired egfr-tki resistance
EP3458064A1 (en) * 2016-05-18 2019-03-27 Boehringer Ingelheim International GmbH Anticancer combination therapy
TWI808958B (en) * 2017-01-25 2023-07-21 美商特普醫葯公司 Combination therapy involving diaryl macrocyclic compounds
US11395821B2 (en) 2017-01-30 2022-07-26 G1 Therapeutics, Inc. Treatment of EGFR-driven cancer with fewer side effects
JP2020510027A (en) * 2017-03-08 2020-04-02 アリアド ファーマシューティカルズ，インコーポレーテッド 5-chloro-N4- [2- (dimethylphosphoryl) phenyl] -N2- {2-methoxy-4- [4- (4-methylpiperazin-1-yl) piperidin-1-yl] phenyl} pyrimidine-2, Pharmaceutical preparation containing 4-diamine
EA202091372A1 (en) 2017-12-05 2020-10-05 Оскотек Инк. PYRROLO (PYRAZOLO) PYRIMIDINE DERIVATIVE AS LRRK2 INHIBITOR
US20240059698A1 (en) * 2022-07-29 2024-02-22 Accutar Biotechnology Inc. Heteroaryl compounds as egfr inhibitors and their uses

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102146059A (en) * 2010-02-08 2011-08-10 上海艾力斯医药科技有限公司 Quinazoline derivatives and preparation method and application thereof
CN103814030A (en) * 2011-09-22 2014-05-21 辉瑞大药厂 Pyrrolopyrimidine and purine derivatives

Also Published As

Publication number Publication date
WO2014140989A2 (en) 2014-09-18
CA2904797A1 (en) 2014-09-18
SG11201506531WA (en) 2015-09-29
MX2015012106A (en) 2016-01-12
TW201446248A (en) 2014-12-16
KR20150119210A (en) 2015-10-23
RU2015137596A (en) 2017-04-17
EP2968336A2 (en) 2016-01-20
WO2014140989A3 (en) 2014-12-04
AU2014229468A1 (en) 2015-09-03
CN105073116A (en) 2015-11-18
IL240730A0 (en) 2015-10-29
AR095197A1 (en) 2015-09-30
JP2014177456A (en) 2014-09-25

Similar Documents

Publication Publication Date Title
BR112015023020A2 (en) combination of egfr t790m inhibitor and egfr inhibitor for the treatment of non-small cell lung cancer
CY1124307T1 (en) PHARMACEUTICAL COMPOSITION, METHODS OF THERAPY AND USES THEREOF
BR112015019995A2 (en) THERAPEUTIC COMBINATION INVOLVING ANTIBODIES AGAINST CLAUDIN 18.2 FOR THE TREATMENT OF CANCER
BR112015026297A2 (en) combination therapy consisting of a tor kinase inhibitor and a substituted 5-quinazolinone compound for cancer treatment
BR112016014410A2 (en) neoantigen vaccine combination therapy
EA201992251A1 (en) ANTI-CANCER VACCINES AND METHODS OF TREATMENT WITH THEIR APPLICATION
EA201491584A1 (en) METHODS OF TREATING NON-SMALL-CELL LUNG CANCER WITH THE USE OF COMBINED TREATMENT WITH KINASE TOR INHIBITOR
BR112016005816A2 (en) COMBINATION OF ANTI-LAG-3 ANTIBODIES AND ANTI-PD-1 ANTIBODIES TO TREAT TUMORS
BR112015026006A2 (en) methods for treating cancer with the use of tor kinase inhibitor combination therapy
BR112015020911A2 (en) antibody, use of a combination and treatment method
BR112014007690A2 (en) treatment of pancreatic cancer and non-small cell lung cancer with inhibitors through
MX2016002645A (en) Combination therapy for the treatment of glioblastoma.
MX2018006674A (en) Cancer treatment using 2-deoxy-2-fluoro-l-fucose in combination with a checkpoint inhibitor.
NI201500150A (en) CANCER TREATMENT WITH DIHYDROPIRAZINE-PIRAZINES × Provided in this method
BR112015026247A2 (en) methods for cancer treatment using tor kinase inhibitor combination therapy
CL2016000379A1 (en) Compositions and therapeutic methods for accelerated pest reduction
BR112015027477A2 (en) Method for Treating a Swallowing Disorder
BR112016027043A8 (en) combination, pharmaceutical composition comprising glucocorticoid and edo-s101, kit and use in cancer treatment
BR112019001398A2 (en) Methods for Prostate Cancer Treatment
MX369609B (en) Synthetic lethality and the treatment of cancer.
BR112018008882A2 (en) method for treating a proliferative disorder and pharmaceutical
ECSP14011792A (en) IAP INHIBITORS
BR112016029012A2 (en) method of treating non-small cell lung cancer and / or small cell lung cancer using thienotriazolodiazepine compounds
BR112019008241A2 (en) treatment of nodular prurigo
BR112016012248A2 (en) nephropathy treatment method

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 4A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]